CY1116543T1 - COMPOSITIONS INCLUDING aP2-SPECIAL ANTI-ORDER FOR THIS USE IN TREATMENT OF DIABETES, DYSANEXIA GLYPYKOSYOS - Google Patents

COMPOSITIONS INCLUDING aP2-SPECIAL ANTI-ORDER FOR THIS USE IN TREATMENT OF DIABETES, DYSANEXIA GLYPYKOSYOS

Info

Publication number
CY1116543T1
CY1116543T1 CY20151100659T CY151100659T CY1116543T1 CY 1116543 T1 CY1116543 T1 CY 1116543T1 CY 20151100659 T CY20151100659 T CY 20151100659T CY 151100659 T CY151100659 T CY 151100659T CY 1116543 T1 CY1116543 T1 CY 1116543T1
Authority
CY
Cyprus
Prior art keywords
glypykosyos
dysanexia
diabetes
treatment
order
Prior art date
Application number
CY20151100659T
Other languages
Greek (el)
Inventor
Gokhan S Hotamisligil
Haiming Cao
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10707783.6A external-priority patent/EP2403605B1/en
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of CY1116543T1 publication Critical patent/CY1116543T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Εκπονείται μέθοδος μείωσης συμπτώματος κλινικής διαταραχής που χαρακτηρίζεται από παρεκκλίνουσα αύξηση κυκλοφορούντος aP2 χορηγώντας σε υποκείμενο αναστολέα εκκρινόμενου aP2, έκκρισης aP2, ή παράγοντα παρεμπόδισης aP2 ορού. Για παράδειγμα, δυσανεξία γλυκόζης μειώνεται μετά από χορήγηση τέτοιου αναστολέα ή παράγοντα. Παραδειγματικές συνθέσεις αναστέλλουν κυτταρική έκκριση aP2 ή δεσμεύονται με aP2 στην κυκλοφορία, μειώνοντας κατ' αυτόν τον τρόπο το επίπεδο ή την δραστικότητα του aP2 σε αίμα ή ορό.A method of reducing the clinical disorder symptom characterized by aberrant circulating aP2 secretion is administered by administering a subject secreted aP2 inhibitor, aP2 secretion, or serum aP2 inhibitor. For example, glucose intolerance is reduced after administration of such an inhibitor or agent. Exemplary compositions inhibit aP2 cellular secretion or bind to aP2 in the circulation, thereby reducing the level or activity of aP2 in blood or serum.

CY20151100659T 2009-03-05 2015-07-29 COMPOSITIONS INCLUDING aP2-SPECIAL ANTI-ORDER FOR THIS USE IN TREATMENT OF DIABETES, DYSANEXIA GLYPYKOSYOS CY1116543T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20925109A 2009-03-05 2009-03-05
US29917010A 2010-01-28 2010-01-28
EP10707783.6A EP2403605B1 (en) 2009-03-05 2010-03-05 Compositions comprising an aP2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance

Publications (1)

Publication Number Publication Date
CY1116543T1 true CY1116543T1 (en) 2017-03-15

Family

ID=58459790

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100659T CY1116543T1 (en) 2009-03-05 2015-07-29 COMPOSITIONS INCLUDING aP2-SPECIAL ANTI-ORDER FOR THIS USE IN TREATMENT OF DIABETES, DYSANEXIA GLYPYKOSYOS

Country Status (1)

Country Link
CY (1) CY1116543T1 (en)

Similar Documents

Publication Publication Date Title
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
BR112015009948A8 (en) Activin-actrii antagonists, uses thereof for treating bone diseases and other disorders, and method for monitoring the effectiveness of treating or preventing a bone disease and other disorders
MX365986B (en) Spiro - fused piperidine derivatives for use as inhibitors of the renal outer medullary potassium channel.
EA200971053A1 (en) METHODS OF TREATMENT OF THE LEAD ULCERS
MA32611B1 (en) Operations for the treatment of thalassemia
EA201200318A1 (en) Heterocyclic oximes
TR201818927T4 (en) Improvement in Catheters
EA201100335A1 (en) PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-ASSOCIATED DISEASES
EA201991014A1 (en) DIABETES TREATMENT
EA201170669A1 (en) TREATMENT OF PYRPHENIDONE PATIENTS WITH ATYPICAL LIVER FUNCTION
BR112013014914A2 (en) compound, pharmaceutical composition, method of treating cancer in a patient and use
BR112013004917A2 (en) systemic allogeneic stem cell therapies for treating diseases in animals.
EA201270666A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING URIC ACID LEVEL
BR112013032265A2 (en) continuous subcutaneous insulin infusion methods with a hyaluronan degradation enzyme
EA200970953A1 (en) SPECIFIC INHIBITORS PDGFRβ
PA8635301A1 (en) SUBSTITUTED DERIVATIVES OF OXAZOLBENZOISOTIAZOL DIOXIDE, PROCEDURE FOR PREPARATION AND USE
MX2014001946A (en) Inhibitors of the renal outer medullary potassium channel.
EA201201186A1 (en) USE OF ERBB3 INHIBITORS IN THE TREATMENT OF NEGATIVE AND BASAL-LIKE BREAST CANCER TREATMENT
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
UY31676A1 (en) "DERIVATIVES OF 3-METHYL-IMIDIAZO- [1,2-B] -PIRIDAZINA"
GT201300235A (en) USE OF 2,3-DIHYDROIMIDAZO (1,2-C) SUBSTITUTED KINAZOLINS
ES2421717T3 (en) Alkaline phosphatase to increase the activity of the immune system in a mammal at risk of inflammatory diseases
ECSP099518A (en) USE OF PIRANONE ACID DERIVATIVES REPLACED FOR THE TREATMENT OF METABOLIC SYNDROME
DK2109608T3 (en) Amide-substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors
GEP201706716B (en) Optimised subcutaneous therapeutic agents